TITLE:
A Study to Evaluate the Safety of Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2600g

CONDITION:
Psoriasis

INTERVENTION:
Raptiva (efalizumab)

SUMMARY:

      This is an open label, multicenter study designed to evaluate the safety and tolerability of
      efalizumab administered subcutaneously at weekly doses of 1.0 mg/kg in subjects with plaque
      psoriasis who previously participated in Study ACD2600g.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: N/A to N/A
Criteria:

        Inclusion Criteria:

          -  Signed informed consent

          -  Previous participation in Study ACD2600g

          -  For women of childbearing potential, continued use of an acceptable method of
             contraception for the duration of the study

        Exclusion Criteria:

          -  Any medical condition that, in the judgment of the investigator, would jeopardize the
             subject's safety following exposure to Efalizumab
      
